InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector
April 21, 2022 07:30 ET
|
InMed Pharmaceuticals Inc.
Expands rare cannabinoid portfolio beyond current CBC and CBTReleases White Paper outlining research into the therapeutic potential of CBDV VANCOUVER, British Columbia and SOUTH SAN FRANCISCO,...
InMed Pharmaceuticals Strengthens its Commercial Leadership Team with the Appointment of Vice President of Sales and Marketing for BayMedica
February 15, 2022 07:30 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...
InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector
January 19, 2022 07:30 ET
|
InMed Pharmaceuticals Inc.
CBT is the first of several rare cannabinoid launches planned for the first half of 2022; includes CBDV and THCVExpands the Company’s rare cannabinoid product portfolio, which also includes...
Registration Now Open For Tribe Public’s Webinar Event "Addressing The Increasing Demand For Rare Cannabinoids" Featuring InMed’s Management Team On January 6, 2022
December 30, 2021 07:30 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Dec. 30, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization...
InMed Pharmaceuticals and BayMedica Participating in Tribe Public’s Webinar "Accelerating The Commercialization of Rare Cannabinoids"
September 17, 2021 07:30 ET
|
InMed Pharmaceuticals Inc.
Registration for the September 21, 2021 event now open VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader...
InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids
September 13, 2021 07:30 ET
|
InMed Pharmaceuticals Inc.
Establishes leadership position in manufacturing and commercialization of rare cannabinoidsPositions InMed within large and growing consumer health and wellness cannabinoid marketsTransitions InMed...
InMed Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 19:18 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare...
InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale Production
June 17, 2021 07:30 ET
|
InMed Pharmaceuticals Inc.
5 g/L cannabinoid yield significantly exceeds reported industry yieldsSignificantly reduces the overall cost of rare cannabinoid manufacturingContinued advancement to GMP-ready large-scale batch...
InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™
April 26, 2021 07:30 ET
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, April 26, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based...